Speed up the process and cut the cost of finding new treatments for Chagas disease and leishmaniasis by bringing together pharmaceutical companies in a multilateral, simultaneous, and non-competitive search process
current phase of drug development
updated 1 Jun 2021
The NTD Drug Discovery Booster was launched in 2015 to circumvent early-stage commercial barriers between pharmaceutical participants, allowing DNDi to search millions of unique compounds simultaneously, using computational approaches to refine the search iteratively, in the hunt for new treatment leads.
‘This experiment could significantly reduce the time and money it takes to find new, promising treatment leads, and echoes the great potential of innovative research and development collaborations.’Dr Bernard Pécoul, Executive Director, DNDi
The innovation of the NTD Drug Discovery Booster not only lies in the multilateral approach, but also in the iterative nature of the search, meaning companies will continually examine their libraries for better matches as the search is refined. This will significantly condense down the time it will take to find new, promising treatment leads.
The NTD Drug Discovery Booster consortium has engaged eight pharmaceutical companies to date: AbbVie, Astellas, AstraZeneca, Celgene (now part of Bristol-Myers Squibb), Eisai, Merck, Shionogi, and Takeda Pharmaceutical Company Limited. The Global Health Innovative Technology Fund (GHIT Fund), which launched in 2013 to assist international global health research and development partnerships, supported the involvement of the four Japanese companies through grants provided to DNDi, including an initial grant of EUR 640,000 (79.5 million Japanese Yen), a second grant of EUR 470,000 (55 million Japanese Yen), and a third grant of EUR 1.2 million (158 million Japanese Yen).
‘IPK joined DNDi’s new initiative, the NTD Drug Discovery Booster programme, that cuts the cost of early-stage drug discovery, accelerates and expands discovery of new drugs for NTDs. In 2016, we identified four hit series that are currently advancing to further development. It is our hope that we can soon identify a breakthrough compound for patients.’David Shum, Group Leader, Assay Development & Screening, Institut Pasteur Korea, South Korea
Since its creation in 2015, the NTD Drug Discovery Booster has launched 45 iterations around 22 seed compounds, with 13 hit series released, of which six have progressed to in vivo proof-of-concept studies for Chagas disease, leishmaniasis or both. Two compounds from one hit series have demonstrated efficacy in a leishmaniasis infection model: one was transitioned into lead optimization and is progressing to the pre-clinical stage with Takeda.
NTD Drug Discovery Booster screening activities were placed on hold in early 2019 to focus efforts on transitioning existing hit series into lead optimization projects. A re-launch of the NTD Drug Discovery Booster is planned for 2022 with a specific focus on Chagas disease.
News & press releases
- 27 July 2020 – Five years of the Neglected Tropical Diseases (NTD) Drug Discovery Booster
- 29 March 2018- DNDi welcomes Astellas to the NTD Drug Discovery Booster
- 18 April 2017 – Merck joins DNDi’s ‘Drug Discovery Booster’ to accelerate discovery of new treatments for neglected diseases
- 15 June 2016 – Celgene joins DNDi’s ‘Drug Discovery Booster’ to accelerate discovery of new treatments for neglected diseases
- 3 August 2015 – Al Jazeera The Cure “Finding a cure for Kala-azar” Click here to watch video
- 30 July 2015 – BioCentury “Neglected attention” Click here to access the article / PDF
- 1 June 2015 – The New York Times “Japanese companies attack neglected diseases” Click here to read the article
- 28 May 2015 – DNDi and four pharmaceutical companies announce ‘Drug Discovery Booster’ experiment
- Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis, RSC Medicinal Chemistry January 2021
NTD Drug Discovery Booster
Get our latest news, personal stories, research articles, and job opportunities.